OncoPharm

This week's pod has lots of updates!

IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. https://doi.org/10.1200/JCO-25-02169

Real world rates of PJP suggest room for improvement in prophylaxis, especially those on corticosteroids + additional immunosuppressants. https://doi.org/10.1177/10600280261443794

Daraxonrasib given expanded access by FDA before approval: https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug

And yes, the ivermectin boom was real: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848862

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice.

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in cancer. First up - Trop2

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Video with slides: https://youtu.be/mrDQyYkaF7A

This week we highlight some promising clinical research in the pancreatic cancer space.

Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter.

A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine).

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Bibliography:

1.. 2019 Systematic Review of Published Cases: https://doi.org/10.1111/dme.14050

2. Mass General Data & Publication: https://jamanetwork.com/journals/jamaoncology/fullarticle/2822927

3. Japanese Claims Data & Pub: https://doi.org/10.1111/jdi.14362

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce.

Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Recapping what I learned at HOPA 2026:

-Beyond steroids for irAs

-IT chemo beyond methotrexate and cytarabine

-Pre-emptive CMV management in patients receiving certain bispecifics

-semaglutide-alectinib drug interaction

-Safety (n = ~40) of MMR vaccine in patients post-Auto transplant on maintenance daratumumab

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI.

Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane?

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies.

RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference?

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Lots of FDA approval updates to discuss from the past few weeks:

-Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC

-Encorafenib approval with cetuximab + FOLFOX

-Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma

-Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL

Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm